25 May 2013
Keywords: mgi, initiates, phase, irofulven/gemzar, trial, pharma, announced
Article | 21 June 2001
MGI Pharma has announced the initiation of a dose-escalating Phase Iclinical trial of its novel anticancer compound irofulven in combination
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 June 2001
18 June 2001
24 May 2013
© 2013 thepharmaletter.com